- recruiting
Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations
This study is for people who might have genetic changes (Factor V Leiden or Prothrombin G20210A) that can increase blood clot risk. It helps confirm if you have these changes, checks your general health, and shows you what being in a clinical trial is like, lasting about 10 weeks.
United Kingdom - recruitingPHASE1
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation
This study is testing a new medicine, CITY-FXI, for safety in healthy adults and those with specific blood clotting conditions. It's the first time this medicine is being given to people to see how their bodies react.
United Kingdom